Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT05909150
Recruiting Phase 2

Hypertonic Saline Solution to Prevent Acute Kidney Injury After Heart Transplantation

NCT05909150 · tracked via the Priya Life Science Brazil tracker
Sponsor
Fernando Bacal
Phase
Phase 2
Started
2023-11-08
Last updated
2026-05-06

Condition(s) studied

Heart TransplantationAcute Kidney Injury

Investigational drug(s) / intervention(s)

Sodium chloride solution 3,5%Sodium chloride solution 0,9%

Sodium chloride solution 3,5%: Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.

Sodium chloride solution 0,9%: Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.

Study summary

The goal of this study is to evaluate if hypertonic saline solution can prevent or attenuate acute kidney injury after heart transplantation in the early postoperative phase.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Hospitalized patients submitted to orthotopic heart transplantation (HT) Exclusion Criteria: * Requirement of renal replacement therapy at the time of HT * Requirement of extracorporeal membrane oxygenation (ECMO) before or immediately after HT * Severe peri-operative mechanical complications * Double transplant (e.g. heart-kidney or heart-lung) * Hypernatremia (Na ≥ 145) * Severe hyponatremia (Na ≤ 120)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Heart Institute, University of São Paulo. São Paulo Brazil Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05909150 on ClinicalTrials.gov ↗ ← All trials in Brazil